All-Star Investor Panel

Tama Copeman

Tama Copeman
Alcyone*7 and
Managing Partner
Maya*7 Investments 

Dr. Tama Copeman is the founder and CEO of Alcyone*7, a management advisory company, and the founder and Managing Partner of Maya*7 Investments, an associated boutique investment company. She has worked globally with and for numerous companies ranging from start up to Fortune 500 in executive-level strategy and risk, business development, competitive analysis, intellectual property strategy, international partnerships, technology and product commercialization. She is the chairman of the board of Mid-Atlantic Diamond Ventures, serves on the steering committee of Mid Atlantic Bio Angels, is an advisor to Ben Franklin Technology Partners, and an external faculty in the Drexel LeBow Center for Corporate Governance.

Pamela DemainPamela R. Demain, MBA, CLP
Executive Director, Corporate Licensing
Merck & Co., Inc.

Pamela Demain is Executive Director, Corporate Licensing at Merck. She has been at Merck for over 30 years. For the past 18 years, she has been responsible for negotiating transactions with companies, universities and institutions worldwide, including arrangements for compounds, research collaborations, patents, formulations and research platform technologies.

Pam also heads up the relationship development area, which includes responsibility for Merck’s partnering outreach program, initiating new business development opportunities and building relationships with companies and universities worldwide. Since 2000, she has been instrumental in the strategic transformation of Merck from an inward-looking to an outward-facing company focused on partnerships with companies and universities worldwide.

Prior to her current position, Ms. Demain was in charge of the Business Information & Research Department in the Worldwide Human Health Marketing area of Merck, providing global strategic decision support for all of Merck’s new and in-line products.

Previous positions at Merck include 13 years in Corporate Planning, Marketing Communications and Product Management, where she was responsible for the worldwide launch of PRIMAXIN/TIENAM. She joined Merck in 1981 as part of the MBA management training program.

Pamela’s pharmaceutical career began in the natural products laboratory of Gruppo Lepetit, an Italian pharmaceutical company, which was then a subsidiary of the Dow Chemical Company. Ms. Demain is a graduate of the University of Massachusetts at Amherst, and holds a M.B.A. in International Business from The American University in Washington, D.C. and is a Certified Licensing Professional (CLP).

Pam has been on the Board of Trustees for the Licensing Executive Society (USA & Canada) since 2006 and is currently Vice President of Communications. She previously was Regional VP for the US, and Trustee for Partnering. Her most recent accomplishments include establishing the LES Insights weekly e-newsletter and the Branding Initiative for LES. She has been a member of the LES Life Sciences Committee since 2003. In 2012, she was honored by LES with the Frank Barnes Mentoring Award.

George T. De Sanctis, Ph.D., F.C.C.P.George T. De Sanctis, Ph.D., F.C.C.P
Director, Scouting & Partnering
Sanofi R&D

George T.  De Sanctis is currently Director, Scouting & Partnering in Sanofi R&D, based in Bridgewater, New Jersey where he has worked at Sanofi and its predecessor companies for the past twelve years. He is working closely with both academia and the biotech industry to seek out new innovative solutions to address the unmet need of patients. He has held several positions including: Head, Respiratory Pharmacology/Pathology, in the Internal Medicine (R&D) at Sanofi-Aventis, Director, Strategy and Open Innovation (R&D) at Sanofi-Aventis and more recently, Director, Scouting & Partnering US, Prospective & Strategic Initiatives at Sanofi. George earned a Bachelor of Science and Masters of Science degree in Medical Physiology at McGill University and a Doctorate in Medical Sciences at the University of Calgary in Canada. He then started his fellowship training in the Pulmonary Division at the University of Alberta and then moved to the US where he completed a Research Fellowship at the Brigham & Women’s Hospital / Harvard Medical School (HMS) in the Division of Pulmonary & Critical Care Medicine. He was then promoted to the positions of Research Associate in Medicine, Instructor in Medicine and Assistant Professor of Medicine at HMS. George has earned numerous awards in academia including two fellowship awards from the Canadian Lung Association and a Glaxo/Medical Research Council of Canada. In recognition of his research endeavours, he was also awarded two young investigator awards from the American College of Chest Physicians, an  Edward Livingston Trudeau Scholar Award from the American Lung Association (Highest Ranking Research Grant Award) at  HMS, a 1st Recipient of the “Partners Investigator Nesson Award”, Brigham & Women’s Hospital and Massachusetts General Hospital, Harvard Medical School and another Partners Investigator Nesson Award the following year. He has 52 full length published reports in numerous peer reviewed journals such as Nature Genetics, Nature Medicine, Science, Journal of Clinical Investigation and The Journal of Experimental Medicine. His research has led to a new understanding of the genetic basis of airway hyperresponsiveness and the immunological basis of inflammation in models of asthma. He has also authored numerous invited reviews and book chapters including the Annual Review of Physiology and the Lung Biology in Health and Disease (Marcel Dekker) Series. George is dedicated to seek out strategically aligned disruptive technologies from the external world into Sanofi and building long sustainable relationships with our partners in academia and the biotech sector.

Dalton Einhorn
Chief Executive Officer
EpiNova Therapeutics

Dalton Einhorn is the co-founder of EpiNova Therapeutics, a virtual oncology-focused small molecule epigenetics therapeutics company. Dalton is a resident of Morris County and has worked for several of New Jersey’s leading pharmaceutical and biotechnology employers, including:  Roche, Daiichi-Sankyo, Novo Nordisk and Johnson & Johnson. He has been an advisor and mentor to the NJ Bio community beginning with his role as a venture capitalist while with J&J’s corporate venture group, JJDC. As a venture investor, he managed a portfolio of approximately $100 million of assets. In addition to starting his current entrepreneurial venture, he advises a range of life science companies in the therapeutics and device sectors. He is an Entrepreneur in Residence for the Moffitt Cancer Center, and also serves as a mentor to life science start-ups at NYU.

Brenda D. GavinBrenda D. Gavin, DVM, MBA
Founding Partner
Quaker Partners

Dr. Brenda Gavin is a founding partner of Quaker Partners. Previously, she was President of S.R. One, Limited (S.R. One), GlaxoSmithKline’s bioscience venture capital investment company, and a general partner of EuclidSR Partners, an independent venture capital limited partnership focused on healthcare and information technology. During Dr. Gavin’s tenure, S.R. One invested in more than 100 life sciences companies and 20 venture funds. Dr. Gavin was responsible for many of the direct venture and strategic investments made by S.R. One, and she served as a board member or active board observer for many of its portfolio companies.

Dr. Gavin is currently a board member of BioLeap, and recently served on the boards of Celator Pharmaceuticals and TetraLogic Pharmaceuticals. In addition, she serves on the boards  of BioAdvance (the Biotechnology Greenhouse Corporation of Southeastern Pennsylvania), and the Pennsylvania State University Research Foundation; she also serves on the International Advisory Board of the Monell Chemical Senses Center. Dr. Gavin is a past board member of Quaker portfolio companies Tengion and Tranzyme Pharma, and is also a past board member of the National Venture Capital Association.

Prior to her career in business, Dr. Gavin held a commission in the U.S. Public Health Service and served in the Epidemic Intelligence Service at the Centers for Disease Control and Prevention in Atlanta.

Dr. Gavin is a graduate of Baylor University. She received her Doctor of Veterinary Medicine from the University of Missouri and her Master of Business Administration from the University of Texas – San Antonio.

Ben GoldbergBen Goldberg
BSG Advisors

Ben is the founder of BSG Advisors, a consulting firm with a practice focused on providing financial and operating management expertise to emerging growth and middle market companies, particularly in the technology, life sciences, cleantech, and advanced manufacturing industries.  He serves these clients as an interim or part-time CFO and/orCOO, or on a project or transaction, such as an acquisition, divestiture or licensing transaction, due diligence, strategic and operational planning and budgeting, business plan and investor presentation development, cash flow management, turnaround and crisis management, financing, or systems selection and implementation.  He also performs due diligence for early stage investors and assists them in transactions.

Prior to founding BSG Advisors, Ben served as CFO of a $20 million manufacturer of packaging materials and a $25 million manufacturer of bar code scanning equipment.  As CFO of the bar code scanning manufacturer, he served as a key member of a team that prepared the registration statement and prospectus for the company’s initial public offering effort.  His experience includes both high growth situations and successful turnarounds.  Earlier in his career, he worked for several Fortune 100 companies in positions in Engineering, Operations, and Financial Management.  He also taught in theGraduateBusinessSchoolatFairleighDickinsonUniversity.  Ben received his Bachelor’s degree in Industrial Engineering fromLehighUniversityand his Master’s degree in Business Administration from theUniversityofDelaware.  He is active in a number of civic and charitable organizations and is a member of the Greater Philadelphia Senior Executives Group, BioStrategy Partners, Regional Biotech Council, MidAtlantic Angel Group, and Financial Executive Networking Group.  He has served as a judge of numerous business plan competitions including the Fox School Business Plan Competition, Mid-Atlantic Diamond Ventures and the Angel Venture Fair, and as a member of theScienceCenter’s QED Program selection team.  He serves as elected Auditor for his Township.

Ben is an active angel investor, as well as an entrepreneur.  He has been a leader in the Mid-Atlantic Angel Group Funds, serving as Treasurer of MAG I, chairman of the MAG I screening committee, member of the MAG I & II executive committees, and has led and participated in numerous due diligence assignments.  He is a member of the board of directors of MAG I portfolio companies NanoPack and Biopticon and the MAG representative to SkillSurvey and Compliance Assurance.  Together with Larry Brotzge of RobinHood Ventures, Ben led the $1.1 million syndication of NanoPack among the four most prominent Philadelphia angel groups – MAG, RobinHood, Delaware Crossing and LORE.

James GolubieskiJames M. Golubieski
New Jersey Health Foundation and Foundation Venture Capital Group

James M. Golubieski is President of New Jersey Health Foundation and its affiliate, Foundation Venture Capital Group (FVCG).

FVCG was established in 2006 by New Jersey Health Foundation to provide pre-seed funding to new life science companies founded by New Jersey researchers to help them advance toward commercialization.

As the President of Foundation Venture Capital Group, Mr. Golubieski works closely with the ten companies in which Foundation Venture has invested, sits on their Boards and provides guidance in helping them to develop their business models.

Previously he had been CFO of Array Medical, Inc., a medical device start-up company established in 1995 that developed a groundbreaking blood test to test platelet function.  The company was sold in 1999.  Mr. Golubieski was also the chief operating officer and senior executive vice president of Glendale National Bank and a member of its board of directors, president of Glendale Investment Corp. and Glendale Mortgage Services, Inc. and chief financial officer of Glendale Bancorp, which was acquired by Mellon Financial., For 10 years prior he had been with KPMG.  

Mr. Golubieski is a member of the New Jersey Economic Development Authority’s Technology Advisory Board, which evaluates and recommends start-up companies for investment.

Kamran HashmiKamran Hashmi
Venture Officer, Technology & Life Sciences Division
New Jersey Economic Development Authority

Kamran Hashmi is a Venture Officer in the EDA’s Technology & Life Sciences division, where he is responsible for marketing the Edison Innovation Fund and technology-led state incentives to potential applicants, consultants, technology transfer offices and partnering organizations such as BioNJ.  He also serves on the board and is a mentor for TechLaunch, a start-up accelerator in NJ.  Kamran graduated from Rutgers University with an MBA in Business Strategy. Before joining the EDA, Hashmi worked in Biotech, RFID, and Logistics firms in a marketing capacity. Kamran also manages individual accounts in EDA’s technology portfolio and has been the department lead in internal CRM and Knowledge Management initiatives. He previously served as Innovation Zone Officer for the Greater New Brunswick Innovation Zone (IZ) and managed a board of key IZ stakeholders.

Evan Myrianthopoulos
Managing Director, Life Science Investment Banking
Aegis Capital Corp.

Evan Myrianthopoulos is Managing Director of the life science investment banking practice at Aegis Capital. Prior to joining Aegis, he was Chief Financial Officer of Soligenix, Inc., a clinical stage biopharmaceutical company based in Princeton NJ where he also served as a Board Director from 2002 until 2012. Prior to Soligenix, Evan was a co-founder and Board Director of Discovery Laboratories, Inc. While at Discovery from 1996 till 2001, Evan held the positions of Chief Financial Officer, Chief Operating Officer, and VP of Finance. He took Discovery public through reverse merger with Ansan Pharmaceuticals, Inc. and also managed its merger with Acute Therapeutics, Inc. During his tenures with Soligenix and Discovery, Evan led 17 financings totaling over $150 million in proceeds, 4 company acquisitions and 13 licensing deals. Prior to co-founding Discovery, Evan was in the venture capital group at Paramount Capital, Inc., a New York City based biotechnology investment bank. Prior to joining Paramount, Evan was a founder and managing partner of S&M Capital Management, a technology focused hedge fund, and also held senior positions in the treasury departments at the National Australia Bank and Merita Bank where he was employed as a spot currency trader. Evan holds a B.A. in Economics and Psychology from Emory University.

Stephen NaglerStephen M. Nagler
Executive Director
MedPro Investors, LLC

Steve Nagler co-founded MedPro Investors, LLC in 2013. MedPro is a rapidly growing organization of healthcare professionals who are accredited investors. MedPro looks to invest in biotech and medical device companies looking to significantly improve the standard of care and demonstrating some degree of clinical efficacy.

Mr. Nagler is also the Founder and Chairman of TriState Ventures, which was active in angel investing for over 20 years. TriState now assists emerging companies in securing institutional investments and corporate partners. He is also a Partner in the law firm, Eaton & Van Winkle LLP.

Mr. Nagler is a graduate of Stuyvesant high School (Captain of the NYC Championship Chess Team), CCNY (President of the Student Body), 1958) and NYU Law School. Upon graduating from NYU Law School he joined the Peace Corps. He served 2 years as a PCV in Malawi, Africa where he participated in the writing of a Magistrates Handbook and taught secondary school. On returning home he worked as a civil rights lawyer, as Executive Director of the ACLU of New Jersey, and as a national advocate for migrant and seasonal farmworkers. He then served as General Counsel of Patlex Corporation where he successfully led the licensing program which financed the Company.

Mr. Nagler was then recruited to be the Executive Director the National Constitution Center and then served as Executive Director of the Commission on Public Understanding of the Law for the American Bar Association. He then served as Counsel and Partner in two Pennsylania and New York law firms where his practice focused on corporate finance, before joining Eaton & Van Winkle LLP as a Partner.

He is married and has two wonderful children. He enjoys skiing and chess (although he is usually defeated by his 12 year old grandson).

Katherine O'NeillKatherine O’Neill
Executive Director
JumpStart New Jersey Angel Network

Katherine O’Neill is the Executive Director for JumpStart New Jersey Angel Network, a member led angel investor group that invests in early stage companies in the Mid-Atlantic region. She is an investor in early stage growth companies. She currently serves on the Board of the Angel Capital Association (ACA) the national organization representing angel investor groups in North America. Katherine represents the ACA at both national and international events.

Katherine is a member of the NJ Economic Development Authority Edison Fund Advisory Board, Ben Franklin Technology Partners of SEPA Advisory Board, NJ Technology CFO Advisory Board, Princeton University MIRTHE Investment Focus Group and Rutgers Innovation Park Advisory Board. In recent years she has spoken at and judged business plan competitions both regionally and nationally at events such as IMPACT, Astia, Microsoft BizSpark NYC competition, Tri State Donald W. Reynolds Cup, Princeton University Jumpstart Innovation Forum, Temple University BOSS bowl and Start Up Weekend Princeton. She is a mentor at regional accelerators Princeton University E-Labs and TechLaunch.

Katherine is a seasoned financial executive and investor in early stage enterprises with extensive experience in start up and entrepreneurial operations as well as operational experiences in a diverse range of businesses.  She has particular expertise developing technology-based business as well as strategic business plans. She has extensive multi-national experience and financial operation management and expertise in healthcare, biotech, pharmaceuticals, information systems, e-commerce and social media. She is the president of O’Neill Associates and consults with growth companies and acts as interim CFO.

In addition to her entrepreneurial activities, she was a senior executive in corporate finance in both a Fortune 100 pharmaceutical company the now GlaxoSmithKline and Fortune 500 chemical company FMC. Katherine has served on many non-profit boards focusing on education and women in business.  Katherine is also currently active with the Forum of Executive Women and the New Jersey Technology Council. Katherine earned a BA in Economics from the University of Maryland Munich, Germany and College Park and a MA in Economics from the University of Pennsylvania.

Lorenzo Pellegrini, Ph.D.
Care Capital, LLC

Gloria RabinowitzGloria Rabinowitz
President and CEO

Gloria V. Rabinowitz is President & CEO, GCM Group LLC., a technology development, strategy, and marketing company.  Before the she founded the GCM Group, she worked for the DuPont Company holding executive level positions across DuPont Strategic Business units in the life sciences and fluoropolymer businesses for over twenty-two years.

She is a Managing Director, Golden Seeds Angel Investor Forum and founded their Philadelphia Forum in 2009.  Golden Seeds ( is a women-friendly angel investor group providing early stage and growth capital to women entrepreneurs across all sectors. Ms. Rabinowitz has judged business plan contests for The Wharton School’s Business Plan Contests and Venture Initiation Programs;  Temple University’s Innovation & Entrepreneurship Institute; and for the French Government’s Cross Innov Business Plan Competition in Nice, France.

In addition she has held adjunct faculty positions in The Graduate Division, The Fox School of Business, Temple University and served as Director, Enterprise Management Consulting also in the Graduate Division, The Fox School of Business.

Her professional and community involvement have included: Current President, Wharton Alumni Club of Philadelphia; Trustees Council of Penn Women; Board of Directors and Treasurer, The Forum of Executive Women of Philadelphia; Board of Directors and Business Development Chair for the West Philadelphia Alliance for Children; Board of Directors, Alliance of Women Entrepreneurs, Philadelphia; She has served on Advisory Boards for Temple University’s International MBA and MBA Programs; MidAtlantic Diamond Ventures of the Innovation & Entrepreneurship Institute.

Ms. Rabinowitz is a Founder of the Women’s MBA Network of Philadelphia.

In addition to her MBA in Finance from The Wharton School she has her Masters in Information Science from The University of Michigan, Ann Arbor, MI.

Yaniv SneorYaniv Sneor
Mid Atlantic Bio Angels

Yaniv Sneor is an entrepreneur, consultant and one of the founders of MABA (Mid Atlantic Bio Angels – a life science angel investment group.

Yaniv has more than 20 years experience starting, running and restructuring companies, in a variety of industries.  During this time, he purchased and sold several companies, structured and managed joint ventures and licenses, and negotiated and executed a broad range of relationships and agreement. In the process, Yaniv conducted due diligence on, and had to evaluate the merit of countless opportunities – from business, market, legal and financial perspectives.

Yaniv has a scientific background, which enables him to understand a broad range of technologies and their significance and relevance in their fields. He is then able to draw upon and utilize his business experience to create effective commercialization strategies through which these technologies can be brought to market and monetized.

Through his consulting practice (Blue Cactus Consulting), Yaniv assists companies with strategy, execution and technology commercialization.

Mina Zion, J.D.Mina W. Zion, J.D.
Director, Technology Commercialization
Rowan University

Mina is the founding director for Rowan’s Office of Technology Commercialization, where he is responsible for developing and marketing the university’s commercial innovation pipeline. He develops and manages Rowan’s patent and licensing portfolios, which comprises of medical innovations from the School of Osteopathic Medicine and the Cooper Medical School. In addition to aligning and de-risking university innovations, Mina collaborates with industry to understand trending unmet market needs and investment opportunities in the biotech and healthcare delivery marketplaces.

Prior to his current appointment, Mina was part of tech transfer offices at the University of Delaware and Stevens Institute of Technology. In industry, Mina was a market manager for BASF Venture Capital and was a member of the corporate M&A integration team at JPMorgan. Mina is also Chief Licensing Officer for Regenerative Technologies, LLC – a startup company interested in marketing a novel osteochondral knee scaffold. Mina earned the Juris Doctorate from Rutgers Law School and the bachelors degree in chemical and biological engineering from New York University.